Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Bellerophon Therapeutics, Inc. (BLPH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.9000-0.1200 (-2.99%)
At close: 4:00PM EDT
Advertisement
Sign in to post a message.
  • D
    D
    What is this I hear about Fabien resigning?
  • B
    Bo
    What's Wang up to? Last filing showed holding approx 1.8MM shares, with approx 1.15MM shares bought at $13 and over 600K shares bought at $4. Almost 20% of the company.
  • G
    Gomez
    He did resign, as of Oct 7. See filing with SEC, available through BLPH website.
  • E
    Erick
    WARREN, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2020.

    http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-provides-clinical-program-update-and-reports-second
    The Investor Relations website contains information about Bellerophon Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
    The Investor Relations website contains information about Bellerophon Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
    investors.bellerophon.com
  • E
    Erick
    WARREN, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the first patient has initiated treatment in the Company’s Phase 3 clinical study of INOpulse® inhaled nitric oxide (iNO) therapy for the treatment of COVID-19 (COViNOX)
    Bullish
  • T
    Timothy
    $BLPH ok so I had 158 shares @13.50 and was planing on selling at $20 bucks for a decent profit. Then I got greedy and pulled my order this AM. Now I have 769 shares on margin @$12.94. I Sold 6000 shares of TTOO for a loss this morning to add to this position. I got in way over my head. I'm looking to exit this week. The sooner the better and I'm willing to leave money on the table if we can just get back to $20 soon. What needs to happen or is the likelihood of that? What happens next with this offering? Any reasonable advice would be great. Thank you very much!
  • s
    sea
    So they planned for 500 enrolled... and got to 200. No outside funding, so I guess that slowed things down. It's safe, or that would have been pointed out by DMC. Does it work? Well, hard to say. If not dead or in RF, then recovery is 90% across cohorts or around 80 to 100% in iNO-arm assuming 50 each arm. Previously was 73% recovery and 6+% mortality in active arm. But disease is not so bad! and treatments have improved esp for those on sup O2. Death and RF is then 0 to 10% now, but with ten data points only, this is a waste of time? So good news for pre-covid investors they got cash at 14, likely got data useful to FDA for the main profitable indications. bad news: spent some on a trial, covid of course would have stopped other trials anyways...
  • S
    Stocks2daytrade
    Good phase 2 data , 1:15 reverse stock split recently so this one has potential , but they will need some cash. Interesting to see when and how they raise their additional capital. A secondary offering is not ruled out.
  • L
    LegalMonster
    Why are you guys selling on this news? Anyone selling on this news of a direct securities offering is not taking the time to look at the facts or understand this is really good news. This is an insider, board member, former Goldman Sachs pro buying more stock!

    This is effectively a direct offering by the company to one of its insiders - Mr. Ted Wang, Phd and Chief Investment Officer of Puissance Capital. It is clear, based on the filed prospectus supplement, that Puissance Capital is likely the "institution" purchasing the shares in this direct public offering of stock. Puissance recently ditributed 534,000 of BLPH to its partners, including Mr. Wang, on April 20th 2020. It's apparent, this instituional investor is buying a significant amount more of BLPH shares for a good reason. This is not only about providing more capital to BLPH, it shows extreme confidence in BLPH and its prospects. It may even be tied to specific clinical trials or governmental funding for its Covid-19 indication.

    Don't react with a noraml knee-jerk reaction or fear of dilution and sell out at loss or lower the cost of the shares which will only make it cheaper for this insider to buy more shares. This is good dilution and a great sign to have insider making a significant institutional investment in BLPH before all the great news and price appreciation occurs. It's still going to be a low float stock and company sitting on more cash and awesome upside. I'm buying more while the uninformed are panic selling for no good reason.

    Here is Ted Wang's resume:

    TED WANG, CIO, New York

    Mr. Wang is CIO of Puissance Capital and brings with him 18 years of global equities trading and investing experience. Mr. Wang was a Partner of Goldman, Sachs & Co and during his 18-year tenure at the firm he held many leadership positions, mostly recently as Co-Head of US Equities Trading and Global Co-Head of One Delta Trading and a member of the Goldman Sachs Risk Committee. At his retirement, he was the most senior Chinese partner at the firm and was deeply involved in the firm’s strategy in China, where he developed extensive relationships with government officials, regulators, corporate and investing clients. Mr. Wang has distinguished himself throughout his career at Goldman Sachs for successfully navigating many volatile markets. He also gained extensive operational expertise while managing various Goldman trading businesses globally, including operations, technology, credit and legal and compliance. Mr. Wang joined Goldman Sachs in 1996, was named Managing Director in 2002, and Partner in 2006. Prior to joining Goldman, Mr. Wang co-founded Xeotron Corp., a company specializing in DNA biochips in Texas. He holds a PhD in Physics from the University of Minnesota, an MBA from the University of Texas, Austin, and a BS from Fudan University, China. He is co-chair of the board of trustees of the Museum of Chinese in America, a trustee of the China Institute, the Dunhuang Foundation, the Spence School, and a member of Committee of 100.

    https://www.advfn.com/stock-market/NASDAQ/BLPH/stock-news/82264418/statement-of-changes-in-beneficial-ownership-4
    Statement of Changes in Beneficial Ownership (4) - Bellerophon Therapeutics, Inc. BLPH
    Statement of Changes in Beneficial Ownership (4) - Bellerophon Therapeutics, Inc. BLPH
    www.advfn.com
  • a
    anthony
    should I buy
  • P
    PAUL
    SEC Filing.FORM S-3
    There are being registered hereunder such indeterminate number of shares of common stock, such indeterminate number of shares of preferred stock, such indeterminate principal amount of debt securities, such indeterminate number of warrants and rights to purchase common stock or debt securities, and such indeterminate number of units, as shall have an aggregate initial offering price not to exceed $150,000,000. If any debt securities are issued at an original issue discount, then the offering price of such debt securities shall be in such greater principal amount as shall result in an aggregate initial offering price not to exceed $150,000,000
    Neutral
  • J
    Jase
    Nitric Oxide is a pulmonary vasodilator — which opens the vessels so there’s better blood flow — which would increase oxygen in the blood stream. I have a hard time believing that it wouldn’t help covid patients who are about to pass away.
    Bellerophon has the potential to do a lot of good in times such as these.
  • D
    D
    Awesom news today: Bellerophon Therapeutics Announces FDA Clears Initiation of Phase 3 Study for INOpulse® Inhaled Nitric Oxide Therapy to Treat COVID-19.http://www.globenewswire.com/news-release/2020/05/11/2031087/0/en/Bellerophon-Therapeutics-Announces-FDA-Clears-Initiation-of-Phase-3-Study-for-INOpulse-Inhaled-Nitric-Oxide-Therapy-to-Treat-COVID-19.html

    Off to the moon folks.. Congratulations who believed. Stock will close above 20 today.
    WARREN, N.J., May 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage...
    WARREN, N.J., May 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage...
    www.globenewswire.com
    Bullish
  • m
    mohd
    they talked about building inventory although he refer it to the phase 3. i think the capital raise was to ramp up production
  • T
    TCup
    The target is $5.00.
  • D
    Dinger II
    This stock came up on my double bottom radar, can someone explain what part of the W we are in? Also, it is not overbought. Shares and float are under 10M.
  • L
    LegalMonster
    Post-offering, BLPH will still have less than 10 million shares outstanding and 6.5 million share float. Approximately $60 million in cash, and larger insider holdings based on the direct offering to board member Wang's institutional investment company. Next, should come, a government funding announcement and the start of the 500 patient clinical trials. Then we go back over $20 with ease.
  • E
    Erick
    2 months ago I shared my guess on this board saying this company might be struggling to recruit covid patients.
    On a separate post I also noted chief medical officer bought some shares.
    Other than disliking and keeping silence I wish we had some brainstorming here and then we would have closed our long positions and open shorts. If we had a discussion maybe we would make some key guesses such as
    1) internally, the trials not going well has been noticed by management in early August and they immediately sacked old cmo
    2) it was also these negative signs that caused long time no news from funding applications.
    3) the new cmo bought very low amount of shares only to show his commitment to his new job, little bit of skin in the game, nothing more.

    I am not saying any of above are true, but these came to mind first.
    Now the question is, what to expect from final report based on data from near 200 patients? Can it make a change in sp, or is the game over?
  • L
    LegalMonster
    The next news that will continue to propel this stock to $45 or higher will be announcment of government funding for this newly approved 500 patient phase 3 sometime soon (within weeks) I assume now that the study is approved by FDA, then annoucnement of 1st patient enrolled, then readouts along the way as the treatment is only ten days long, then last patient enrolled, and quick study results thereafter. Hopefully, continued favorable results and safty, then approve for use in Covid-19 indication. No need to worry about getting product to market because it's already widely distributed and available.
  • D
    D
    Nitric Oxide inhalation as a treatment is going to be a very effective way in treating individuals diagnosed with Covid-19. Not only will this reduce the need for Hospital admittance, it can also be combined with other drugs such as a diuretic to significantly reduce the load on the lungs allowing individuals to effectively fight off the virus and develop the necessary antibodies to combat it in the future. The possibilities are limitless once it tests effective...and it will!
Advertisement
Advertisement